AI Article Synopsis
- Recent research indicates that patients who are in remission from major depressive disorder (MDD) still face cognitive issues, which may be linked to their levels of serum anticholinergic activity (SAA).
- The study involved 49 remitted MDD patients and 165 healthy controls, using cognitive tests to compare their performance based on SAA levels.
- Results showed that patients with higher SAA levels performed worse on cognitive tests compared to healthy individuals, suggesting that anticholinergic activity from antidepressants could negatively impact cognitive function even after remission.
Article Abstract
Background: A recent meta-analysis has found that patients who have achieved remission of major depressive disorder (MDD) show cognitive dysfunction. Moreover, anticholinergic activity levels are associated with cognitive dysfunction, although the extent of these effects is unclear. Therefore, we measured serum anticholinergic activity (SAA) in blood samples of patients with remitted MDD and examined its relationship with cognitive function.
Methods: We recruited 49 patients with remitted MDD following treatment and 165 healthy subjects. Subjects completed the Stroop test and the logical memory (LM) and visual reproduction (VR) subtests from the Wechsler Memory Scale-Revised. We compared cognitive function scores among those with SAA below the limit of quantification (SAA [-]), those with SAA above the limit of quantification (SAA [+]), and healthy controls.
Results: The SAA (+) group scored significantly lower (p < 0.001) than the healthy control group on all tests, and the VR score of the SAA (-) group was significantly lower than that of the healthy control group (p = 0.024). LM scores in the SAA (+) group were significantly lower than that of the SAA (-) group (p = 0.033). Multiple regression analysis revealed a significant effect of SAA on the LM score (p = 0.015).
Limitations: Our study was a cross-sectional analysis of a small number of patients.
Conclusions: Our results support previous findings that the anticholinergic effect of antidepressants adversely affects cognitive function. Additionally, the cognitive impairment observed may persist because of MDD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2024.09.152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The value of diabetes technology enabled coaching (DTEC) to support remission evaluation of medical interventions in T2D: Patient and health coach perspectives.
PLOS Digit Health
January 2025
School of Nursing, McMaster University, Hamilton, Ontario, Canada.
The multicomponent Remission Evaluation of Medical Interventions in T2D (REMIT) program has shown reduction of hazard of diabetes relapse by 34-43%, but could benefit from improved ability to scale, spread, and sustain it. This study explored, at the conceptualization phase, patient and health coach perspectives on the acceptability, adoption, feasibility, and appropriateness of a digital REMIT adaptation (diabetes technology enabled coaching (DTEC)). Twelve semi-structured interviews were conducted with patients (n = 6) and health coaches (n = 6) to explore their experiences with the REMIT study, opportunities for virtualisation, and a cognitive walkthrough of solution concepts.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Cog-Aging Research Group, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
Background: Studies comprising cohorts of cognitively unimpaired older adults or with mild cognitive impairment (MCI) that assesses clinical and biological characteristics to conversion to dementia are scarce in Brazil.
Method: To determine the median conversion time to dementia in a cohort of Brazilian older adults with low educational levels. In the cohort, participants undergo an annual comprehensive clinical and neuropsychological evaluation, complemented by neuroimaging and laboratory assessments to determine the diagnosis.
PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Int J MS Care
January 2025
Novartis Pharmaceuticals UK Ltd, London, United Kingdom.
Background: The PANORAMA survey aimed to assess current treatment practice for individuals with new diagnoses of relapsing-remitting multiple sclerosis (RRMS) in the United Kingdom and to explore variations in treatment approaches with an emphasis on escalation vs early high-efficacy treatment (HET) and treatment goals.
Methods: Health care professionals (HCPs) from the UK treating patients with RRMS took part in interviews facilitated by a structured questionnaire. Data were analyzed descriptively using quantitative or qualitative methods, as appropriate.
Disseminated enterovirus infection treated with intravenous immunoglobulin in a patient on maintenance ocrelizumab for multiple sclerosis.
BMJ Case Rep
January 2025
Infectious Diseases, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
We present a case of a woman in her 40s with disseminated enterovirus infection in the setting of maintenance therapy with ocrelizumab for relapsing-remitting multiple sclerosis. The patient originally presented with fever, bilateral lower limb swelling and hypoalbuminaemia. She subsequently developed a productive cough and diarrhoea, and a viral respiratory multiplex panel detected rhino/enterovirus.
View Article and Find Full Text PDFProtective Effects of Heat-Killed Lactobacilli against Plasma-Induced Neurotoxicity in Multiple Sclerosis.
Probiotics Antimicrob Proteins
January 2025
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.
Heat-killed lactobacilli seem to have protective effects against oxidative stress and neurotoxicity. This study aimed to evaluate the antioxidant properties of specific heat-killed lactobacilli extracts and determine their neuroprotective effects against the neurotoxicity induced by blood plasma from people with multiple sclerosis (MS). The antioxidant activity of the three heat-killed lactobacilli was measured using the DPPH assay.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!